Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Exploiting synthetic lethality: The next generation

Next generation synthetic lethal target discovery using high-throughput CRISPR technology


09 Sep 2022


Exploiting synthetic lethality: The next generation


Cancer Biology;  Targeted Therapy;  Molecular Oncology

Tumour Site

Colon and Rectal Cancer


Matthew Garnett


M. Garnett

Author affiliations

  • Wellcome Trust Sanger Institute, CB10 1SA - Cambridge/GB


Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.